Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Cancer-associated mutations reveal a novel role for EpCAM as an inhibitor of cathepsin-L and tumor cell invasion

Fig. 3

Wild type, but not C66Y EpCAM, can inhibit CTSL activity. a, b EpCAM expression negatively correlates with CTSL activity in a panel of cancer cell lines. EpCAM expression was measured by flow cytometry, and CTSL activity was measured using a fluorescent substrate. c Recombinant EpCAM inhibits CTSL activity. Increasing doses of recombinant EpCAM were added to conditioned media from SKOV-3 cells (source of CTSL). CTSL activity was measured after 30 min. d Wild type, but not C66Y EpCAM, inhibits CTSL activity. A549 cells were stably transduced with GFP, wild type EpCAM or C66Y EpCAM. Endogenous CTSL activity was measured. e, f Wild type EpCAM and EpCAM deletion mutants containing the TY-1 domain, can inhibit CTSL activity. A549 cells were stably transduced with the indicated EpCAM deletion mutants, and endogenous CTSL activity was measured

Back to article page